SUMMARY

• RYBREVANT is administered in combination with carboplatin and pemetrexed intravenously (IV) weekly (QW) for 4 weeks, with the initial RYBREVANT dose as a split infusion in Week 1 on Day 1 and Day 2, then every 3 weeks starting at Week 7 until disease progression or unacceptable toxicity. Administer premedications before each RYBREVANT infusion as recommended. When administering RYBREVANT in combination with carboplatin and pemetrexed, infuse pemetrexed first, carboplatin second, and RYBREVANT last.¹
• RYBREVANT is administered as a single agent IV QW for 5 weeks, with the initial dose as a split infusion in Week 1 on Day 1 and Day 2, then every 2 weeks starting at Week 7 until disease progression or unacceptable toxicity. Administer premedications before each RYBREVANT infusion as recommended.¹
• Monitor patients for any signs and symptoms of infusion reactions during RYBREVANT infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.¹
• RYBREVANT administration was permitted in outpatient settings per the clinical trial protocol for the phase 1 CHRYSALIS study.²
• Please refer to the DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS sections of the full Prescribing Information.¹

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 19 June 2024.